Prostate Cancer Guidelines on
... scientific evidence is a very important factor, but it has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned (2-4). ...
... scientific evidence is a very important factor, but it has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned (2-4). ...
Guidelines on Prostate Cancer - European Association of Urology
... The EAU Prostate Cancer Guidelines Panel are most grateful for the support and considerable expertise provided by Prof.Dr. J-P. Droz, Emeritus Professor of Medical Oncology (Lyon, France) for the topic of ‘Management of prostate cancer in senior adults’. As a leading expert in this field, and promin ...
... The EAU Prostate Cancer Guidelines Panel are most grateful for the support and considerable expertise provided by Prof.Dr. J-P. Droz, Emeritus Professor of Medical Oncology (Lyon, France) for the topic of ‘Management of prostate cancer in senior adults’. As a leading expert in this field, and promin ...
(NCCN Guidelines®) Uterine Neoplasms
... • "Primary Treatment" for patients not suitable for primary surgery: Recommendation revised, "Pelvic RT ± brachytherapy and/or Chemotherapy or Hormone Systemic therapy". • Footnote "a" revised: "Endometrial biopsy is typically not useful in diagnosing malignancies of the uterine wall such as stromal ...
... • "Primary Treatment" for patients not suitable for primary surgery: Recommendation revised, "Pelvic RT ± brachytherapy and/or Chemotherapy or Hormone Systemic therapy". • Footnote "a" revised: "Endometrial biopsy is typically not useful in diagnosing malignancies of the uterine wall such as stromal ...
Muscle-invasive and Metastatic Bladder Cancer
... and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality *Modified from (4). The EAU Guidelines Office does not perform cost assessments or review ...
... and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality *Modified from (4). The EAU Guidelines Office does not perform cost assessments or review ...
Muscle-invasive And Metastatic Bladder Cancer
... and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor - has to be balanced against benefits and burdens, values and preferences and cost when a grade is assigned (5-7). The EAU Guidelin ...
... and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor - has to be balanced against benefits and burdens, values and preferences and cost when a grade is assigned (5-7). The EAU Guidelin ...
(NCCN Guidelines®) Uterine Neoplasms
... circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines ...
... circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines ...
Melanoma - Wikipedia, the free encyclopedia
... produce the dark pigment, melanin, which is responsible for the color of skin. These cells predominantly occur in skin, but are also found in other parts of the body, including the bowel and the eye (see uveal melanoma). Melanoma can originate in any part of the body that contains melanocytes. ...
... produce the dark pigment, melanin, which is responsible for the color of skin. These cells predominantly occur in skin, but are also found in other parts of the body, including the bowel and the eye (see uveal melanoma). Melanoma can originate in any part of the body that contains melanocytes. ...
Muscle-invasive and Metastatic Bladder Cancer
... Separate EAU guidelines documents are available addressing upper urinary tract tumours [1], nonmuscle-invasive bladder cancer (Ta,T1 and carcinoma in situ) [2], and primary urethral carcinomas [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts but ...
... Separate EAU guidelines documents are available addressing upper urinary tract tumours [1], nonmuscle-invasive bladder cancer (Ta,T1 and carcinoma in situ) [2], and primary urethral carcinomas [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts but ...
Muscle-invasive and Metastatic Bladder Cancer
... Bladder cancer (BC) is the ninth most commonly diagnosed cancer worldwide, with more than 380,000 new cases each year and more than 150,000 deaths per year, and an estimated male-female ratio of 3.8:1.0 [6]. At any one time, 2.7 million people have a history of urinary BC [7]. ...
... Bladder cancer (BC) is the ninth most commonly diagnosed cancer worldwide, with more than 380,000 new cases each year and more than 150,000 deaths per year, and an estimated male-female ratio of 3.8:1.0 [6]. At any one time, 2.7 million people have a history of urinary BC [7]. ...
An overview of funding to cancer research
... This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for an ...
... This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for an ...
Cancer Research in Australia
... This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for an ...
... This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for an ...
Testicular Cancer - European Association of Urology
... occurring per 100,000 males/per year in Western society [2-5]. Its incidence has been increasing during the last decades especially in the industrialised countries [6-8]. Data from the Surveillance Epidemiology and End Results (SEER) program (1973 to 1998) show a continuing increased risk among Cauc ...
... occurring per 100,000 males/per year in Western society [2-5]. Its incidence has been increasing during the last decades especially in the industrialised countries [6-8]. Data from the Surveillance Epidemiology and End Results (SEER) program (1973 to 1998) show a continuing increased risk among Cauc ...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
... further evaluation of possible chest, spinal, diaphragmatic, or vascular involvement based on CT imaging. d Assessment by multidisciplinary team with experience in malignant pleural mesothelioma. e See Principles of Supportive Care (MPM-A). f Observation for patients who are asymptomatic with minima ...
... further evaluation of possible chest, spinal, diaphragmatic, or vascular involvement based on CT imaging. d Assessment by multidisciplinary team with experience in malignant pleural mesothelioma. e See Principles of Supportive Care (MPM-A). f Observation for patients who are asymptomatic with minima ...
Penile Cancer - European Association of Urology
... on penile cancer (National Comprehensive Cancer Network [2], French Association of Urology [3] and the European Society of Medical Oncology [4]). In this 2015 EAU Guidelines compilation, all standard information on levels of evidence (LE) and grading of recommendations (GR) has been taken out of the ...
... on penile cancer (National Comprehensive Cancer Network [2], French Association of Urology [3] and the European Society of Medical Oncology [4]). In this 2015 EAU Guidelines compilation, all standard information on levels of evidence (LE) and grading of recommendations (GR) has been taken out of the ...
From research to policy and practice
... and reports. These have all focused on providing short- to medium-term benefits for people with terminal illness and their carers, families and friends. This report contains details of our research and its impact in 2014/15, highlighting some of the projects that have influenced policy and practice. ...
... and reports. These have all focused on providing short- to medium-term benefits for people with terminal illness and their carers, families and friends. This report contains details of our research and its impact in 2014/15, highlighting some of the projects that have influenced policy and practice. ...
Curriculum Vitae - Augusta University
... Premature Infants, Research Initiation Grant, CWRU, State of Ohio, $5,000. 1996-98 Principal Investigator, Effects of Nonnutritive Sucking on Heart Rate, Vagal Tone, and Oxygenation in Preterm Infants, Total award, $11,600; 1996 FPB small research grant, $5,000, The Foundation for Neonatal Research ...
... Premature Infants, Research Initiation Grant, CWRU, State of Ohio, $5,000. 1996-98 Principal Investigator, Effects of Nonnutritive Sucking on Heart Rate, Vagal Tone, and Oxygenation in Preterm Infants, Total award, $11,600; 1996 FPB small research grant, $5,000, The Foundation for Neonatal Research ...
Solicitations and Deadlines, August 2015
... November 4: Short-Term Measurements of Improved Physical and Molecular Resilience in Pre-Clinical Models (R01) November 16: End of submission window for the following NIH Extramural Loan Repayment Programs (LRP): Clinical Researchers (LRP-CR); Pediatric Research (LRP-PR); Health Disparities Research ...
... November 4: Short-Term Measurements of Improved Physical and Molecular Resilience in Pre-Clinical Models (R01) November 16: End of submission window for the following NIH Extramural Loan Repayment Programs (LRP): Clinical Researchers (LRP-CR); Pediatric Research (LRP-PR); Health Disparities Research ...
NATIONAL ACTION PLAN FOR OVARIAN CANCER RESEARCH
... • Differences in reporting content across not-for-profit organisations highlight the need to adopt a higher standard of reporting to include the amount and purpose of research funding allocated by funders. It would be desirable for donors to obtain information on the inputs into the research they a ...
... • Differences in reporting content across not-for-profit organisations highlight the need to adopt a higher standard of reporting to include the amount and purpose of research funding allocated by funders. It would be desirable for donors to obtain information on the inputs into the research they a ...
cancer research
... funding, and the announcement will be made in May 2009 • 17 members of the five “Dream Teams” are affiliated with NCI-designated Cancer Centers ...
... funding, and the announcement will be made in May 2009 • 17 members of the five “Dream Teams” are affiliated with NCI-designated Cancer Centers ...
Applicant Details - Beatson Cancer Charity
... Beatson Cancer Charity is committed to providing significant funding and services to enhance the experience, treatment, outcomes and wellbeing of current and former cancer patients and their families/carers in partnership with the Beatson West of Scotland Cancer Centre. Beatson Cancer Charity provid ...
... Beatson Cancer Charity is committed to providing significant funding and services to enhance the experience, treatment, outcomes and wellbeing of current and former cancer patients and their families/carers in partnership with the Beatson West of Scotland Cancer Centre. Beatson Cancer Charity provid ...
te National Cancer Institu Advancing Global Cancer Research through
... Today, more so than any other time in our history, we have an opportunity to work together to decrease the global burden of cancer. In 2008 alone, nearly 7.6 million people worldwide died from cancer1 and by 2030 the number of cancer deaths may be as high as 13.1 million due to population growth and ...
... Today, more so than any other time in our history, we have an opportunity to work together to decrease the global burden of cancer. In 2008 alone, nearly 7.6 million people worldwide died from cancer1 and by 2030 the number of cancer deaths may be as high as 13.1 million due to population growth and ...
View doc
... Cancer, or malignant tumour, is a disease category that is defined by abnormal cell growth and their unusual spreading. In recent years, several advances were presented in investigating and understanding molecular and cellular mechanisms that cause tumor development, as well as necessary biomarkers ...
... Cancer, or malignant tumour, is a disease category that is defined by abnormal cell growth and their unusual spreading. In recent years, several advances were presented in investigating and understanding molecular and cellular mechanisms that cause tumor development, as well as necessary biomarkers ...
Guide to applicants for grants from the Priority
... Has a relationship with, or interest in, an organisation, which is likely to interfere with or restrict the applicant in carrying out the proposed activities fairly and independently; or ...
... Has a relationship with, or interest in, an organisation, which is likely to interfere with or restrict the applicant in carrying out the proposed activities fairly and independently; or ...
Guide to applicants for grants from the Priority
... Has a relationship with, or interest in, an organisation, which is likely to interfere with or restrict the applicant in carrying out the proposed activities fairly and independently; or ...
... Has a relationship with, or interest in, an organisation, which is likely to interfere with or restrict the applicant in carrying out the proposed activities fairly and independently; or ...
Shao-Cong Sun, Ph.D.
... Tenure-Track Investigator, National Center for Human Genome Research, NIH Acting Chief, Genetics and Molecular Biology Branch, NHGRI ...
... Tenure-Track Investigator, National Center for Human Genome Research, NIH Acting Chief, Genetics and Molecular Biology Branch, NHGRI ...
National Institutes of Health
The National Institutes of Health (NIH) is a biomedical research facility primarily located in Bethesda, Maryland. An agency of the United States Department of Health and Human Services, it is the primary agency of the United States government responsible for biomedical and health-related research. The NIH both conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.With 1,200 principal investigators and more than 4,000 postdoctoral fellows in basic, translational, and clinical research, the IRP is the largest biomedical research institution in the world, while, as of 2003, the extramural arm provided 28% of biomedical research funding spent annually in the U.S., or about US$26.4 billion.The NIH comprises 27 separate institutes and centers that conduct research in different disciplines of biomedical science. The IRP is responsible for many scientific accomplishments, including the discovery of fluoride to prevent tooth decay, the use of lithium to manage bipolar disorder, and the creation of vaccines against hepatitis, Haemophilus influenzae (HIB) and human papillomavirus (HPV).